Kura Oncology, Inc. (KURA)
Nasdaq · Pharmaceutical Preparations · Manufacturing · CIK 1422143 · fiscal year ends in Dec
Closing price $10.57 on 29 Oct 2026; 52-week range $7.40 to $13.59.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $77.2M
- Net income, last twelve months
- -$296.8M
- Earnings per share
- -$3.37
- Operating margin
- -411.9%
- Net margin
- -384.3%
- Free cash flow
- -$117.4M
- Return on equity
- -612.8%
- Market value
- $940.2M
- Cash
- $70.2M
- Debt
- $9.8M
- Debt to equity
- 0.20
- Shares outstanding
- 89.0M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $67.5M | -$303.6M | -$278.7M | -$3.18 | -$70.7M | 10-K filed 5 Mar 2026 |
| FY2024 | 31 Dec 2024 | $53.9M | -$193.2M | -$174.0M | -$2.02 | $133.8M | 10-K filed 28 Feb 2025 |
| FY2023 | 31 Dec 2023 | $0 | -$165.8M | -$152.6M | -$2.08 | -$125.0M | 10-K filed 5 Mar 2026 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $20.9M | -$68.3M | -$0.77 |
| Q1 FY2026 | 31 Mar 2026 | $18.3M | -$73.3M | -$0.83 |
| Q4 FY2025 | 31 Dec 2025 | $17.3M | -$81.0M | -$0.92 |
| Q3 FY2025 | 30 Sep 2025 | $20.8M | -$74.1M | -$0.85 |
| Q2 FY2025 | 30 Jun 2025 | $15.3M | -$66.1M | -$0.75 |
| Q1 FY2025 | 31 Mar 2025 | $14.1M | -$57.4M | -$0.66 |
Company events
The newest 8-K filings of 149 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 9 Sep 2026 | 8-K | Other events | 8.01 |
| 8 Sep 2026 | 8-K | Leadership change | 5.02 |
| 12 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 29 Jul 2026 | 8-K | Leadership change | 5.02 |
| 4 Jun 2026 | 8-K | Leadership change, Shareholder vote | 5.02, 5.07, 9.01 |
| 12 May 2026 | 8-K | Results | 2.02, 9.01 |
| 5 Mar 2026 | 8-K | Results | 2.02, 9.01 |
| 29 Jan 2026 | 8-K | Bylaws or fiscal year change | 5.03, 9.01 |
| 12 Jan 2026 | 8-K | Results | 2.02, 9.01 |
| 2 Dec 2025 | 8-K | Other events | 8.01 |
| 13 Nov 2025 | 8-K | Other events | 8.01 |
| 4 Nov 2025 | 8-K | Results | 2.02, 9.01 |
Every filing
The newest filings with the SEC of 338 held.
| Filed | Form | Period |
|---|---|---|
| 9 Sep 2026 | 8-K | 9 Sep 2026 |
| 8 Sep 2026 | 8-K | 8 Sep 2026 |
| 12 Aug 2026 | 10-Q | 30 Jun 2026 |
| 12 Aug 2026 | 8-K | 12 Aug 2026 |
| 29 Jul 2026 | 8-K | 24 Jul 2026 |
| 4 Jun 2026 | S-8 | – |
| 4 Jun 2026 | 8-K | 4 Jun 2026 |
| 26 May 2026 | DEFA14A | – |
| 12 May 2026 | 10-Q | 31 Mar 2026 |
| 12 May 2026 | 8-K | 12 May 2026 |
| 10 Apr 2026 | ARS | 31 Dec 2025 |
| 10 Apr 2026 | DEFA14A | – |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 29 Sep 2026 | Ford Kathleen, Chief Operating Officer | Sale under a trading plan | 3,668 | $10.75 | $39.4K | 142,986 | 29 Sep 2026 |
| 29 Sep 2026 | Leoni Mollie, Chief Medical Officer | Sale outside a trading plan | 28,802 | $10.75 | $309.6K | 141,095 | 29 Sep 2026 |
| 29 Sep 2026 | Powl Brian T., Chief Commercial Officer | Sale outside a trading plan | 15,430 | $10.75 | $165.9K | 136,819 | 29 Sep 2026 |
| 28 Sep 2026 | Bair Teresa Brophy, Chief Legal Officer | Sale under a trading plan | 8,442 | $10.50 | $88.6K | 187,002 | 29 Sep 2026 |
| 28 Sep 2026 | Ford Kathleen, Chief Operating Officer | Sale under a trading plan | 6,906 | $10.50 | $72.5K | 146,654 | 29 Sep 2026 |
| 28 Sep 2026 | Leoni Mollie, Chief Medical Officer | Sale outside a trading plan | 12,448 | $10.50 | $130.7K | 169,897 | 29 Sep 2026 |
| 28 Sep 2026 | Doyle Thomas James, SVP, Finance & Accounting | Sale outside a trading plan | 4,607 | $10.50 | $48.4K | 142,428 | 29 Sep 2026 |
| 28 Sep 2026 | Powl Brian T., Chief Commercial Officer | Sale outside a trading plan | 9,020 | $10.50 | $94.7K | 160,249 | 29 Sep 2026 |
| 28 Sep 2026 | Powl Brian T., Chief Commercial Officer | Sale outside a trading plan | 8,000 | $10.56 | $84.5K | 152,249 | 29 Sep 2026 |
| 24 Sep 2026 | Burrows Francis, Chief Scientific Officer | Sale outside a trading plan | 20,726 | $10.83 | $224.5K | 42,327 | 25 Sep 2026 |
| 24 Aug 2026 | Wilson Troy Edward, President and CEO | Purchase | 100,000 | $12.39 | $1.2M | 479,194 | 24 Aug 2026 |
| 21 Aug 2026 | Powl Brian T., Chief Commercial Officer | Sale under a trading plan | 4,345 | $11.89 | $51.7K | 169,269 | 24 Aug 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 29 Sep 2026 | KATHLEEN FORD, Officer | 3,668 | $38.9K | 29 Sep 2026 |
| 29 Sep 2026 | BRIAN POWL, Officer | 15,430 | $163.7K | 29 Sep 2026 |
| 29 Sep 2026 | MOLLIE LEONI, Officer | 28,802 | $305.6K | 29 Sep 2026 |
| 28 Sep 2026 | DOYLE THOMAS JAMES, Officer | 4,607 | $49.6K | 28 Sep 2026 |
| 28 Sep 2026 | FORD KATHLEEN, Officer | 6,906 | $74.3K | 28 Sep 2026 |
| 28 Sep 2026 | BRIAN POWL, Officer | 8,000 | $86.1K | 28 Sep 2026 |
| 28 Sep 2026 | BAIR TERESA BROPHY, Officer | 8,442 | $90.8K | 28 Sep 2026 |
| 28 Sep 2026 | POWL BRIAN T, Officer | 9,020 | $97.1K | 28 Sep 2026 |
| 28 Sep 2026 | LEONI MOLLIE, Officer | 12,448 | $133.9K | 28 Sep 2026 |
| 24 Sep 2026 | FRANCIS J BURROWS, Officer | 20,726 | $224.5K | 24 Sep 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 27 Oct 2026 | BlackRock, Inc. | 13G amended | 8.9% | 7.9M |
| 14 Aug 2026 | Montanova Capital, LLC | 13G amended | 9.7% | 8.6M |
| 15 May 2026 | Armistice Capital, LLC | 13G amended | 4.23% | 3.7M |
| 30 Apr 2026 | Vanguard Capital Management | 13G | 5.01% | 4.4M |
| 27 Mar 2026 | The Vanguard Group | 13G amended | 0% | 0 |
| 17 Feb 2026 | Armistice Capital, LLC | 13G amended | 5.67% | 4.9M |
| 9 Feb 2026 | STATE STREET CORPORATION | 13G | 5.7% | 4.9M |
| 14 Nov 2025 | Armistice Capital, LLC | 13G amended | 5.37% | 4.7M |
| 14 Nov 2025 | BIOTECHNOLOGY VALUE FUND L P | 13G amended | 9.99% | 8.7M |
Trades by members of the House
From each member's periodic transaction report.
| Traded | Member | Type | Amount | Disclosed |
|---|---|---|---|---|
| 12 Dec 2022 | Christopher L. Jacobs (NY27) | Purchase | $1,001 - $15,000 | 20 Jan 2023 |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 14.3M | -0.69% | 8.58 |
| 30 Sep 2026 | 14.4M | -2.7% | 7.73 |
| 15 Sep 2026 | 14.8M | +10.46% | 8.79 |
| 31 Aug 2026 | 13.4M | +2.23% | 4.79 |
| 14 Aug 2026 | 13.1M | -0.27% | 8.83 |
| 31 Jul 2026 | 13.2M | -4.16% | 11.81 |
| 15 Jul 2026 | 13.7M | -9.01% | 7.71 |
| 30 Jun 2026 | 15.1M | +3.35% | 8.57 |
Funds that hold it
From each fund's latest Form 13F.
247 funds held it at 30 Jun 2026: 116 added and 64 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| BlackRock, Inc. | 10,509,233 | $115.3M | +871,702 |
| Montanova Capital, LLC | 8,575,422 | $94.1M | 0 |
| BVF Inc. | 8,445,769 | $92.7M | 0 |
| State Street Corp. | 5,329,208 | $58.5M | +817,317 |
| Vanguard Capital Management LLC | 3,916,164 | $43.0M | +130,479 |
| Armistice Capital, LLC | 3,678,000 | $40.3M | -58,000 |
| AQR Capital Management LLC | 3,126,727 | $34.3M | +1,002,247 |
| Goldman Sachs Group Inc. | 2,265,171 | $24.8M | +831,700 |
| Geode Capital Management, LLC | 2,229,958 | $24.5M | +195,682 |
| Alethea Capital Management, LLC | 2,167,938 | $23.8M | +638,569 |
Peers
Companies in the same industry.
- Eli Lilly & Co. (LLY): revenue $86.5B, market value $1.29T
- Johnson & Johnson (JNJ): revenue $99.3B, market value $662.4B
- AbbVie Inc. (ABBV): revenue $64.4B, market value $513.9B
- Merck & Co., Inc. (MRK): revenue $66.6B, market value $361.0B
- Novartis AG (NVS): revenue $54.5B, market value $307.3B
- AstraZeneca PLC (AZN): revenue $58.7B, market value $270.6B
- Abbott Laboratories (ABT): revenue $46.6B, market value $180.9B
- Novo Nordisk A/S (NVO): revenue $46.8B, market value $174.8B
- Pfizer Inc. (PFE): revenue $63.7B, market value $170.7B
- Vertex Pharmaceuticals Inc. (VRTX): revenue $12.6B, market value $136.8B